Source:http://linkedlifedata.com/resource/pubmed/id/14534359
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0020792,
umls-concept:C0086418,
umls-concept:C0205088,
umls-concept:C0669120,
umls-concept:C1167622,
umls-concept:C1314939,
umls-concept:C1415300,
umls-concept:C1511545,
umls-concept:C1514562,
umls-concept:C1709915,
umls-concept:C1711351,
umls-concept:C1880389,
umls-concept:C1883204,
umls-concept:C1883221
|
pubmed:issue |
3
|
pubmed:dateCreated |
2003-12-3
|
pubmed:abstractText |
N-Methyl-d-aspartate (NMDA) receptors play key roles in both physiological processes, particularly synaptic plasticity, and in neuropathological states such as epilepsy and acute neurodegeneration. R-(R*,S*)-alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenyl-methyl)-1-piperidine propanol (RO 25-6981), is a high-affinity and selective blocker of NMDA receptors containing the NR2B subunit. Using site-directed mutagenesis, [3H]RO 25-6981 binding, Xenopus oocyte voltage-clamp recordings, and molecular modeling, we have identified several critical residues involved in the RO 25-6981 binding site within the N-terminal LIVBP-like domain of the human NR2B subunit. Two mutations, NR2B(D101A) and NR2B(F176A), resulted in a complete loss of [3H]RO 25-6981 binding and also abolished the high-affinity RO 25-6981-mediated inhibition of NMDA-induced currents. The mutation NR2B(T233A) led to a marked reduction in binding affinity by 13-fold. Mutations F182A, D104A, or K234A had a more moderate influence on the binding affinity (KD values increased by 8-, 7-, and 6-fold, respectively). In a three-dimensional model of the NR2B LIVBP-like domain based on the X-ray crystal structure of the amino-terminal domain of the mGlu1 receptor, the critical residues are located in the central cleft where interaction with RO 25-6981 may stabilize the closed structure of the domain. Our results suggest that the three amino acids Asp-101, Phe-176, and Thr-233 are important molecular determinants for the high-affinity binding of RO 25-6981 to the LIVBP-like domain of human NR2B. A possible binding mode for RO 25-6981 is proposed.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Complementary,
http://linkedlifedata.com/resource/pubmed/chemical/Excitatory Amino Acid Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/NR2B NMDA receptor,
http://linkedlifedata.com/resource/pubmed/chemical/Phenols,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, N-Methyl-D-Aspartate,
http://linkedlifedata.com/resource/pubmed/chemical/Ro 25-6981
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-3565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
307
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
897-905
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:14534359-Animals,
pubmed-meshheading:14534359-Binding Sites,
pubmed-meshheading:14534359-Blotting, Western,
pubmed-meshheading:14534359-Cell Membrane,
pubmed-meshheading:14534359-Cells, Cultured,
pubmed-meshheading:14534359-DNA, Complementary,
pubmed-meshheading:14534359-Excitatory Amino Acid Antagonists,
pubmed-meshheading:14534359-Humans,
pubmed-meshheading:14534359-Models, Molecular,
pubmed-meshheading:14534359-Mutagenesis, Site-Directed,
pubmed-meshheading:14534359-Patch-Clamp Techniques,
pubmed-meshheading:14534359-Phenols,
pubmed-meshheading:14534359-Piperidines,
pubmed-meshheading:14534359-Point Mutation,
pubmed-meshheading:14534359-Receptors, N-Methyl-D-Aspartate,
pubmed-meshheading:14534359-Transfection,
pubmed-meshheading:14534359-Xenopus
|
pubmed:year |
2003
|
pubmed:articleTitle |
Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.
|
pubmed:affiliation |
Pharma Division, Discovery Research CNS, F-Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. parichehr.malherbe@roche.com
|
pubmed:publicationType |
Journal Article
|